JMP Securities upgraded Sarepta Therapeutics Inc (NASDAQ:SRPT) to Outperform in a statement released earlier today.
- Updated: September 19, 2016
JMP Securities has upgraded Sarepta Therapeutics Inc(NASDAQ:SRPT) to Outperform in a report released on Monday September 19 2016.
Previously on 7/22/2016, Needham released a statement for Sarepta Therapeutics Inc(NASDAQ:SRPT) bumped the target price from $20.00 to $26.00. At the time, this suggested an upside of 0.15%.
Only yesterday Sarepta Therapeutics Inc (NASDAQ:SRPT) traded 91.30% higher at $51.30. SRPT’s 50-day moving average is $26.16 and its 200-day average is $20.47. With the last close up 163.13% relative to the 200-day moving average, compared to the Standard & Poor’s 500 Index which has fallen -0.01% over the date range. 29,541,278 shares of the stock were exchanged, up from ann average trading volume of 2,328,380.
See Graph Below:
Sarepta Therapeutics Inc has a 52 week low of $8.00 and a one-year high of $56.18. Sarepta Therapeutics Inc’s total market value is currently $0.0.
In addition to JMP Securities reporting it’s stock price target, a total of 13 brokers have released a ratings update on the stock. The 12-month target stock price is $20.77 with three analysts rating the company a strong buy, one firm rating the stock a buy, five firms rating the stock a hold, four analysts rating the company to underperform, and finally one brokeragerating the company as sell.
General Company Details For Sarepta Therapeutics Inc (NASDAQ:SRPT)
Sarepta Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the discovery and development of ribonucleic acid (RNA)-targeted therapeutics for the treatment of rare, infectious and other diseases. The Company operates in one segment: the development of pharmaceutical products on its own behalf or in collaboration with others. The Company, through its platform technologies, targets a range of diseases and disorders through RNA-targeted mechanisms of action. The Company is also developing therapeutics using its technology for the treatment of drug-resistant bacteria and infectious, rare and other human diseases. The Company’s lead Duchenne Muscular Dystrophy (DMD) product candidate, Eteplirsen, and is an antisense phosphorodiamidate morpholino oligomer (PMO) therapeutic in Phase III clinical development for the treatment of individuals with DMD having an error in the gene coding for dystrophin that is amenable to skipping exon 51.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.